Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Microbiology

Background:

• Vancomycin-resistant enterococci (VRE) are a major cause of hospital-acquired bloodstream infections (BSIs), associated with high morbidity and mortality.
• Limited treatment options and emerging resistance complicate VRE BSI management, necessitating strategies for antimicrobial dose optimization.
• Challenges include drug dosing, resistance, persistent bacteremia, and infective endocarditis treatment.

Purpose of the Study:

• To provide an overview of current treatment strategies for VRE BSIs.
• To discuss the role of therapeutic drug monitoring (TDM) in optimizing antimicrobial therapy for VRE infections.
• To highlight challenges and future perspectives in managing VRE BSIs.

Main Methods:

• Review of existing literature on VRE BSI treatment and therapeutic drug monitoring (TDM).
• Analysis of evidence for TDM in predicting drug toxicity and efficacy of VRE-active agents.
• Discussion of clinical management challenges and future research directions.

Main Results:

• Therapeutic drug monitoring (TDM) shows the most evidence for predicting drug toxicity with daptomycin, linezolid, and teicoplanin.
• Significant gaps exist in predicting antimicrobial efficacy for VRE BSIs using TDM.
• Optimizing antimicrobial dosing through TDM is a key area for supporting clinical infection management.

Conclusions:

• Effective management of VRE BSIs requires careful consideration of treatment options and antimicrobial dosing.
• Therapeutic drug monitoring (TDM) plays a vital role in optimizing antimicrobial therapy, particularly for toxicity prediction.
• Further research is needed to address gaps in predicting antimicrobial efficacy for VRE BSIs through TDM.